Molybdenum (Mo)-containing materials are emerging as highly promising biomaterials in intracranial and cardiovascular medicine, attributable to the distinctive properties of metallic Mo, including its superior mechanical strength, electrical conductivity, consistent corrosion behavior, favorable radiopacity, and the functional versatility of Mo-based nanomaterials.1 However, their biological safety within the cardiovascular and cerebrovascular domains remains unknown.